Showing results (141-150 of 195) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2024
Efficacy and Safety of Taletrectinib in Chinese Patients With <i>ROS1+</i> Non-Small Cell Lung Cancer: The Phase II TRUST-I StudyWei Li, Anwen Xiong, Nong Yang, et al.
Signal Transduction and Targeted Therapy|August 13, 2023
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trialYunpeng Yang, Jie Min, Nong Yang, et al.
Cell Cycle (Georgetown, Tex.)|October 5, 2020
SUFU mediates EMT and Wnt/β-catenin signaling pathway activation promoted by miRNA-324-5p in human gastric cancerYin Peng, Xiaojing Zhang, Huijuan Lin, et al.
Cancer Letters|November 8, 2016
MiRNA-194 activates the Wnt/β-catenin signaling pathway in gastric cancer by targeting the negative Wnt regulator, SUFUYin Peng, Xiaojing Zhang, Qiang Ma, et al.
Cancer Cell|June 21, 2024
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trialQing Zhou, Yi Pan, Xuening Yang, et al.
Cancer Immunology, Immunotherapy : CII|January 5, 2022
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trialJifang Gong, Junning Cao, Qingyuan Zhang, et al.
Eclinicalmedicine|August 18, 2023
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trialYuanyuan Zhao, Gang Chen, Jianhua Chen, et al.
Chinese Medical Journal|May 26, 2026
Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trialKejing Tang, Fengying Wu, Fang Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2022
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion StudyYuankai Shi, Yanqiu Zhao, Sheng Yang, et al.
Signal Transduction and Targeted Therapy|June 16, 2026
Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trialYi Pan, Xuening Yang, Qing Zhou, et al.
Pageof 20